RECRUITING

EUS-guided Ablation of Pancreatic Cyst Neoplasms

Talk to us

Conditions

Pancreatic Cyst

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a registry that will maintain prospective data on the clinical outcomes of all patients with pancreatic cyst lesions who undergo EUS-guided alcohol ablation.

Official Title

Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cyst Neoplasms

Quick Facts

Study Start:2016-06-01
Study Completion:2025-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02422147

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Benign branch-duct intraductal papillary mucinous neoplasm (IPMN) or mucinous cyst neoplasm (MCN) measuring \>2 and up to 4cm in size and located in the head or body of the pancreas.
  2. 2. Benign branch-duct IPMN or MCN measuring \> 2 and up to 4cm in size and located in the tail of the pancreas in a high-risk surgical candidate.
  3. 3. A branch-duct IPMN or MCN with high-risk features (mural nodule or enlarging in size) in a high-risk surgical patient.
  4. 4. Indeterminate cyst lesions
  1. 1. Cysts measuring \<2cm or \>4cm.
  2. 2. Multiloculated cysts (\>4 locules).
  3. 3. Cysts with vascular supply.
  4. 4. Cysts communicating with the main pancreatic duct via an obvious side-branch measuring 2mm or more in diameter.
  5. 5. Cysts with hypoechoic mass lesions that on fine needle aspiration (FNA)reveal malignant cells.
  6. 6. Recent history of pancreatitis and EUS findings suggestive of a pseudocyst.
  7. 7. Bleeding tendency; international normalized ratio (INR) \>1.4 or platelet count \<70,000.

Contacts and Locations

Study Contact

Muhammad Hasan, MD
CONTACT
407-303-2570
Muhammad.Hasan.MD@adventhealth.com

Principal Investigator

Muhammad Hasan, MD
PRINCIPAL_INVESTIGATOR
AdventHealth

Study Locations (Sites)

AdventHealth
Orlando, Florida, 32803
United States

Collaborators and Investigators

Sponsor: AdventHealth

  • Muhammad Hasan, MD, PRINCIPAL_INVESTIGATOR, AdventHealth

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-06-01
Study Completion Date2025-12-01

Study Record Updates

Study Start Date2016-06-01
Study Completion Date2025-12-01

Terms related to this study

Additional Relevant MeSH Terms

  • Pancreatic Cyst